AGEN 2034

Drug Profile

AGEN 2034

Alternative Names: AGEN2034

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agenus; Ludwig Institute for Cancer Research
  • Developer Agenus
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 11 Apr 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Monotherapy) in USA (Parenteral) (NCT03104699)
  • 09 Mar 2017 Agenus plans a phase Ib trial in Cancer (Combination therapy)
  • 30 Nov 2016 Agenus plans a phase I trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top